FAT1 and acute myeloid leukemia: In the Venetoclax-AML cohort, when using CR/CRi, PR, and NR as efficacy classifications, there was no statistically significant difference between FAT1 mutant patients and wild-type patients in the CR/CRi rate (85.71% vs. 62.06%) and PR rate (14.29% vs. 12.64%) after initial induction chemotherapy (p > 0.05, Figure 4A).